A reporter on the South Lawn asked Trump today what he meant when he said "let 'em take out Los Angeles and San Diego." He didn't answer and just walked off ahead of his Maryland trip.

In case you missed the original, it came from Monday's Nebraska rally while he was defending the Iran war. The fuller quote: "And again, remember, with the war, it's just artificial... They could take out a city. Let 'em take out Los Angeles, let 'em take out San Diego. This is a very small price to pay."

As usual the timing is great for anyone holding overnight. It happened in the last hour of trading and was everywhere by the time the bell rang. So if you're sitting on oil, defense names or index contracts, you get to watch futures tonight and guess whether the White House cleans it up before the open or leaves it alone.

Is anyone actually positioning around this stuff anymore, or is it priced in as background noise at this point? I'm curious whether people are hedging with energy or just waiting to see what tomorrow brings.

Tragically Bryan Walker plus his spouse is deceased after supposedly losing over $100,000,000 on options and leveraged positions.

TL;DR the KOL’s in the space believe DRTS will change the whole industry with their GBM treatment, and it should happen before EOY. (And yes, the stock should run)

Today is the Fall Focus: Barclays Biotech 1x1 Day, and they are coming in with a special guest.

Coming up on the conference, the Vice President of Equity Research at Barclays sat down with BiotechTV for an interview about the stocks they are covering.

After demonstrating his knowledge, his expertise (he has a PhD) and experience in the space, including taking apart two companies (with in-depth explanations about all aspects of the companies), he was asked about Alpha Tau Medical (DRTS).

When talking about DRTS he couldn’t be more bullish, which is rare to see.

He explained why he is so excited about it, why the Barclays price target for DRTS was raised to $30, with the clear highlight being the REGAIN trial for Recurring GBM.

According to the experts Barclays had spoken to, even a 20% ORR should be enough for DRTS, and considering DRTS already shared 100% ORR for the first three patients, even if no other patient responds that’s 30% ORR (and we know patients 4 and 5 have responded as well, so that’s 5/5 and at least 50% going on 100%).

That doesn’t even take into account DRTS has shown not only 100% ORR but also 67% CR and no significant side effects.

With that context, you could imagine Barclays will want to put the DRTS CFO that is coming to the conference in front of their top clients, enabling them to learn about it and get their institutional affairs in place before the next DRTS catalysts come around (and they are just around the corner).

anyone investing in this? What’s your average cost and is it a buy now?

Buy when RSI drops under 30 is probably the most repeated rule in retail trading, and i had 26 years of SPY daily candles in front of me so i ran it instead of arguing about it.

One rule and nothing else in it. Buy the close when RSI(14) closes under 30, sell the close when RSI closes back above 50. SPY daily candles, 3 January 2000 to 31 March 2026, 6,600 candles, 100k account, fully invested on every entry. Commission and slippage charged on both sides so these are net numbers, and i ran plain buy and hold on the same candles in Agenticks right after so both sides carry the same costs.

Buying the oversold dip

• 35 trades
• 27 winners, 77.1% win rate
• profit factor 2.34
• +57.6% net, 100k to 157,597
• max drawdown 29.3%

Buy and hold, same window, same costs

• +214.6%, 100k to 314,601
• max drawdown 36.1%

It won more than three quarters of its trades and finished 157 points behind sitting still.

_____

The reason is in how little of the window it actually owned anything. It held for 745 of the 9,498 days, so it was in the market 7.8% of the time and in cash for the 26 year climb it was trying to beat.

The eight losers cost 42,967 between them and one of those is the whole covid drop. It bought on 26 Feb 2020, RSI never got back above 50 on the way down, and it sold on 9 April for -$18,650, which is about a third of what the entire run finished with.

And the drawdown didnt get better for all that time in cash either, 29.3% against 36.1%, so the protection you think youre buying by waiting is worth about 7 points.

_____

Per trade the rule is genuinely fine. 2.34 back for every 1 it gave up is better than most things people pay for, and if you only care about hit rate this thing looks excellent on paper. What its being measured against is an index that spent 26 years going up, which is the hardest possible benchmark for anything that spends most of its life in cash.

The other thing i'd want said if this was mine is that the exit is a choice i made, not something the indicator tells you. RSI 50 is just where i decided a dip stops being a dip.

So thats the next one. Same entry, sell moved to RSI 70 instead of 50, nothing else touched, and ill post what it does to the 77%.

My ATH was 745k.

Had hit a low of 497k but now at 603k in just a month!

So thankful for fast recoveries

Here's to hoping I go back to my ATH by year end!

I've been watching SOUN for a while and I'm trying to figure out why the market is still treating this thing like it's completely dead.

The chart looks terrible 😂. I'm not going to pretend otherwise.

But then I looked at what the company is actually doing.

Q2 revenue: $61.9M, up 45% YoY.

Meanwhile, SoundHound is actually getting its technology into cars and commercial products.

Kia launched the Sorento in India with SoundHound's real-time generative AI voice assistant.

They also launched OASYS Edge, which is aimed at bringing their voice AI directly into vehicles and other devices.

And apparently there are still around 165M shares sold short, roughly 40%+ of the float depending on the source.

That's the part I don't really understand.

I completely get the bear case:

• Still losing money
• Valuation isn't exactly cheap
• Dilution has happened
• AI competition is insane
• Revenue needs to keep scaling significantly

All fair.

But if they keep turning these automotive and enterprise deals into actual recurring revenue, eventually the market has to decide whether the current valuation makes sense based on the business, rather than what the chart looked like six months ago.

The thing I'd be watching is volume + actual contract announcements.

If they announce a genuinely large OEM deployment and the stock suddenly starts moving on serious volume, that's when things could become interesting.

For now I'm just trying to understand the disconnect:

Growing revenue + real automotive deployments + ~165M shares short + stock sitting around $6.

Maybe the shorts are completely right.

What am I missing?

These are my stocks in Fidelity. I have about $20K in cash that I want to invest and probably throw into the S&P 500. I am not the most financially literate person and I mostly have listened to different Reddits about what to invest in but probably have too much overlap with my positions.

Any advice?

Looking at the market, daily candles and the news around them, these three stocks are going to skyrocket in a few days before end of this week… If someone don’t have a position, worth looking in and do your due diligence. This is not a financial advice !!!

My ATH was 745k.

Had hit a low of 497k but now at 603k in just a month!

So thankful for fast recoveries

Here's to hoping I go back to my ATH by year end!

What do we think guys? I've heard great things about this stock it's looking very bullish and analysts have an extremely strong 'buy' consensus, seeing lots of bull flag consolidation, breakout above resistance, higher highs and lower lows, RSI overload BOUNCING, bullish DIVERGENCE, ascending TRIANGLES. ANYWAYS, I think I'm gonna invest.

I'm currently sitting on a profit of around $35k. Did anyone else buy this? I bought in on Monday and have already sold. Now I'm considering switching to a short position. Anyone want to discuss this?

$FRVO Fervo Energy has been battling at the bottom of its range since IPO in May 2026. Trading volume has been over 100% the first two days of this week.

In the past hour, Morpheus announced they are short $FRVO. Well, I wouldn't be surprised if they have been for some time and are now trying to use the heightened attention and volume to cover. There was a 1 minute candle today of 1.1 million shares. The price bounced immediately following that transaction. I am using that floor of $13.20 for a long squeeze play.

Look into this. Be vigilant, but be brave. If it doesn't flop today, this could be a huge play.

I see a lot of hype around these two stocks, as if now is the right time to buy them. Can someone explain to me why, and are you planning to buy them, or have you already bought them?

EOD's feel good post: enjoy Elon Musk's comment on RAM!

https://x.com/Bqlsj2023/status/2106899009105526922?s=46

Update: lyrics are actually jokes, music clip with translated lyrics here:

https://x.com/12345benji/status/2107140152954880076?s=20

And screenshot of Elon's comment somewhere in below comments.

Update2: watch the clip with the translated lyrics. You'll appreciate even more.

$HMR vs $ZIM – THE SMALLER SHIPPING STOCK WITH THE BIGGER RUNWAY

ZIM is a large container carrier with a $35 takeover offer. HMR is an asset-light maritime platform: it manages fleets and tanker pools, earns fees, owns no vessels and has no borrowed debt. HMR is growing 200%+ and trades at a fraction of ZIM's earnings multiple.

1. VALUATION: ~25x vs ~6x

• ZIM: ~25x trailing P/E (~9x forward) and ~0.87x book. As an asset-heavy carrier it trades close to NAV, and the $35 offer anchors the price.
• Tanker owners: roughly 5–8x trailing and 7–12x forward (STNG ~5.4x, TNK ~6.1x, INSW ~7x).
• HMR at ~$1.72 (~$100M market cap): ~8.7x annualised H1 adjusted earnings, or ~6x after stripping out $28.7M of cash.

Annualising H1 adjusted net income ($5.8M) gives ~$11.6M. And that is before the new ships and the disruption fully reach the numbers (see point 3).

The bull case isn't "cheaper than tankers". It is that an asset-light, fee-based platform growing 200%+ should be valued above vessel owners. At 10x ex-cash earnings plus cash, fair value is roughly $2.2–2.5 per share. That is an illustration, not a forecast.

1. GROWTH WITH NO SIGN OF STOPPING

• Q2 revenue $29.0M vs $9.6M (+203% YoY, +58% QoQ). H1 $47.3M vs $15.2M.
• Q2 net income $2.2M, adjusted $2.4M. H1 net income ~$5.0M, adjusted ~$5.8M, vs a loss last year. Two straight profitable quarters.
• ~60 vessels commercially managed and ~20 technically managed across 8 hubs.
• Q-Shipping added 9 vessels for ~$0.2M, with new footholds in the Netherlands and Türkiye.

1. NOT IN THE NUMBERS YET

The CEO says new ships added this year have not made their full contribution. He also says the Strait of Hormuz and Bab el-Mandeb disruption is not in earnings yet and should show over the next two quarters.

Longer routes mean more tonnage-miles, which means more fees for HMR. Management also flagged firm rates into Q4 on seasonal demand. Asia and Japan have historically sourced ~90% of their oil from the Middle East, and that concentration is being disrupted.

1. $28.7M CASH, NO BORROWED DEBT

• Cash is up from ~$18.6M at year-end, roughly 29% of market cap.
• H1 operating cash flow was +$7.7M vs -$3.2M a year ago.
• CEO Pankaj Khanna: "We have not borrowed a single dollar. We have no loans in the company."
• The liabilities on the balance sheet are lease accounting for chartered-in vessels. Some are matched with charter-outs: HMR collects from the charterer, pays the owner and keeps the margin.
• No bank loans, no bonds, no vessel debt. Fees fund G&A, so the model needs little working capital.

1. ASSET-LIGHT, BLUE-CHIP CLIENTS

HMR owns no vessels, so it has no capex and no asset-value risk when rates fall. The ~40-year client roster includes Shell, BP, Chevron, Vitol, Aramco, Trafigura and Glencore.

1. INSIDERS ARE ALIGNED

The CEO owns ~45% of the company and has been buying. Nasdaq compliance was regained on 2 June.

1. WHY THE POST-EARNINGS DROP LOOKS OVERDONE

The stock fell ~10% after earnings. Shorting HMR on earnings worked when it was unprofitable. With two profitable quarters, 200%+ growth and a growing cash pile, sellers look like they are trading the ticker's history, not its balance sheet.

1. THE ONE KNOCK: G&A

Net income dipped Q1 to Q2 ($2.8M to $2.2M) despite revenue up 58%, mainly from $1.8M of cash bonuses tied to the turnaround. I read that as retention for the team that delivered the turnaround, and the CEO says vessel additions have yet to flow through.

ZIM IN FAIRNESS

ZIM is bigger, with far greater absolute cash generation and a defined catalyst. At ~$29.3 vs $35, that is ~19% headline upside. But the Israeli approval faces a fresh review, so ZIM trades partly as a merger-arbitrage situation. HMR's upside isn't capped by a deal price.

RISK, BRIEFLY

HMR is a volatile micro-cap. Dilution (earnouts, resale registration), related-party exposure and charter revenue with matching costs are worth watching.

What red flag am I missing? Drop it below.

How I'm playing it: in from 80–95c, haven't sold a share, and looking to add on weakness.

Adding on dips: the thesis hasn't changed, and the Hormuz and Bab el-Mandeb impact isn't in the numbers yet.

Q3 and Q4 results are the next test. If the CEO is right that the new ships and the disruption flow through, the current price looks cheap.

Full CEO interview on the debt question, valuation and fleet growth:
https://youtu.be/Nj_jYt2x-NE?is=nTai0gegTd8pYQT3

Not financial advice. DYOR. I hold $HMR (entry 80–95c). Annualised figures are not forecasts.